ArticleBritish journal of clinical pharmacology2011
Clinical importance of the CYP2C19*17 variant allele for voriconazole.
Article in British journal of clinical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Predictors of Voriconazole Trough Concentrations in Patients with Child-Pugh Class C Cirrhosis: A Prospective Study.Antibiotics (Basel, Switzerland) · 2021Article
- Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.Scientific reports · 2019Article
- Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.The pharmacogenomics journal · 2016Article
- Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.International journal of clinical pharmacy · 2015Article
- Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Current fungal infection reports · 2015Article
- Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Pharmacogenomics · 2014Article
- Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity.AIDS research and therapy · 2014Article
- Regulatory polymorphisms in CYP2C19 affecting hepatic expression.Drug metabolism and drug interactions · 2013Article
- A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine.British journal of clinical pharmacology · 2012Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.